BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics (ANTX)AN2 TherapeuticsCompany update

Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and

Related news

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

SCYXSCYNEXIS2026-09-28 11:30 EST

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

IMNNImunon2026-09-10 13:30 EST

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-11-04 21:00 EST

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

Stock data

Close
3.96 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States